Xue Fen, Li Duanshu, Hu Chaosu, Wang Zhuoying, He Xiayun, Wu Yi
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Oncotarget. 2017 Feb 28;8(9):15934-15942. doi: 10.18632/oncotarget.12785.
Poorly differentiated thyroid carcinoma (PDTC) is a rare and aggressive malignancy with high rates of invasion and distant metastasis. This study was to explore the ability of intensity-modulated radiotherapy (IMRT) combined with chemotherapy to manage unresectable PDTC. Between February 2011 and April 2012, 5 patients with unresectable PDTC were treated by IMRT at our institution and were included in this analysis. The median radiotherapy dose to the gross tumor volume (GTV) was 66 Gy/33 fractions/6.4 weeks. All patients received chemotherapy, and one patient with tumor compression symptoms had a tracheotomy before treatment. The mean survival time of the 5 patients was 41.6 months. The direct causes of death were distant metastases (40%) and progression of the locoregional disease (20%). In conclusion, IMRT combined with chemotherapy for unresectable PDTC might be beneficial to improve locoregional control. Further new therapies are needed to control metastases.
低分化甲状腺癌(PDTC)是一种罕见的侵袭性恶性肿瘤,具有较高的侵袭率和远处转移率。本研究旨在探讨调强放疗(IMRT)联合化疗治疗不可切除PDTC的能力。2011年2月至2012年4月,我院对5例不可切除的PDTC患者进行了IMRT治疗,并纳入本分析。大体肿瘤体积(GTV)的中位放疗剂量为66 Gy/33次/6.4周。所有患者均接受化疗,1例有肿瘤压迫症状的患者在治疗前进行了气管切开术。5例患者的平均生存时间为41.6个月。死亡的直接原因是远处转移(40%)和局部区域疾病进展(20%)。总之,IMRT联合化疗治疗不可切除的PDTC可能有利于改善局部区域控制。需要进一步的新疗法来控制转移。